Salute e Benessere
BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape | DelveInsight
BAVENCIO is a human antibody targeting programmed death ligand-1 (PD-L1). Preclinical studies have demonstrated its ability to activate both adaptive and innate immune responses. By inhibiting the interaction between PD-L1 and PD-1 receptors, BAVENCIO helps restore T cell-mediated antitumor immunity in preclinical models. In November 2014 , Merck KGaA, Darmstadt, Germany , and Pfizer formed a strategic partnership to jointly develop and commercialize BAVENCIO.
In the U.S., BAVENCIO is approved for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed after first-line platinum-based chemotherapy. It is also indicated for patients with locally advanced or metastatic UC who experience disease progression during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based treatment.
Additionally, BAVENCIO in combination with axitinib is approved in the U.S. for the first-line treatment of patients with advanced renal cell carcinoma. The FDA has also granted accelerated approval for BAVENCIO in the treatment of adults and pediatric patients (12 years and older) with metastatic Merkel cell carcinoma, based on tumor response rate and duration of response. Continued approval may depend on further clinical trials confirming its benefits. Currently, BAVENCIO is approved in 50 countries for at least one indication.
Learn more about BAVENCIO projected market size for merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma @
Urothelial carcinoma is the most common cancer of the urinary system, arising from urothelial cells and primarily affecting individuals over the age of 50. It is more prevalent in males, with an incidence rate two to three times higher than in females. According to DelveInsight's analysis, new cases of urothelial carcinoma were reported across the 7MM in 2023.
The standard treatment primarily involves chemotherapy, particularly cisplatin-based regimens. For patients who do not respond to initial systemic therapy, immunotherapy—using agents such as atezolizumab and pembrolizumab—serves as a secondary option. In some cases, surgical interventions like nephroureterectomy are also performed. Approved treatment options for urothelial carcinoma include , among others.
The urothelial carcinoma treatment market is projected to experience substantial growth, rising from in 2023 at a notable CAGR through 2034, driven by the introduction of innovative therapies currently in clinical trials. However, challenges such as treatment complications in elderly patients and dependence on blood transfusions may pose barriers to market expansion.
Dive deep into an in-depth assessment of the
Merkel cell carcinoma is a rare and aggressive neuroendocrine skin cancer that originates from Merkel cells—specialized mechanoreceptors located at the dermo-epidermal junction responsible for touch sensation. According to DelveInsight's estimates, approximately new cases of MCC were reported in the 7MM in 2023, with the United States accounting for of these cases.
Several approved treatments for MCC are currently available, primarily focusing on immune modulation. Notable therapies include BAVENCIO, a monoclonal antibody developed by ; (pembrolizumab), a PD-1 inhibitor from ; and (retifanlimab-dlwr), a PD-1 inhibitor co-developed by and .
DelveInsight's analysis estimates that the MCC treatment market in the 7MM was valued at approximately in 2023. Over the forecast period from 2024 to 2034, this market is expected to grow at a , driven by the introduction of innovative therapies.
Discover more about the Merkel cell carcinoma market in detail @
Renal cell carcinoma is the most prevalent form of kidney cancer, comprising approximately 90% of all cases. It ranks among the ten most common cancers worldwide. The prognosis for advanced RCC remains poor, with a five-year survival rate of around 11-12%. Research indicates that RCC accounts for the vast majority of kidney cancer cases.
Over the past decade, the treatment landscape for advanced RCC has evolved significantly, driven by the introduction of novel therapies and advancements in surgical and ablative techniques. Treatment approaches have become increasingly personalized, with prognostic groups established to tailor interventions based on disease severity.
For patients in good health with isolated metastases, surgical excision, radiotherapy, or ablative therapy may be recommended to postpone systemic treatment. Meanwhile, those ineligible for surgical removal may benefit from alternatives such as cryoablation, thermal ablation, or stereotactic ablative body radiation therapy. Additionally, targeted treatments like tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies have become essential in both first- and second-line therapy, offering effective management options for advanced RCC.
The market outlook for advanced RCC appears promising, driven by ongoing innovations and the expansion of therapeutic options. As investigational treatments advance through clinical trials, they have the potential to significantly improve patient outcomes and address existing gaps in care. The competitive landscape is rapidly evolving, with developments in targeted therapies, immunotherapies, and combination treatments aiming to enhance survival rates and quality of life for patients with advanced RCC.
For more insights on the evolving landscape of renal cell carcinoma, visit @
The urothelial carcinoma pipeline is highly dynamic, with promising new therapies in development, including (AstraZeneca), (Pfizer), (MedPacto), (Tyra Biosciences), (Taiho Oncology), (UroGen Pharma), and others.
In the Merkel cell carcinoma space, the potential emerging competitors of BAVENCIO include (TuHURA Biosciences), (Philogen), (Immunomic Therapeutics), (Phio Pharmaceuticals/AgonOx), (Kymera Therapeutics), (Merus N.V.), and others.
Key companies such as (Zanzalintinib (XL092) + Nivolumab), (Savolitinib + Durvalumab), (Ciforadenant (CPI-444)), (Abexinostat), (NKT2152), and others are involved in developing drugs for advanced RCC.
To know more about the number of competing drugs in development, visit @
Discover how BAVENCIO is shaping the merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma treatment landscape @
BAVENCIO, co-developed by Merck KGaA and Pfizer, is an primarily approved for urothelial carcinoma and Merkel cell carcinoma. Its key differentiation lies in its first-in-class approval for maintenance therapy in locally advanced or metastatic urothelial carcinoma, setting it apart from competitors like (pembrolizumab) and (atezolizumab). However, in the broader immuno-oncology (IO) landscape, BAVENCIO faces that dominate indications in lung, renal, and other cancers.
BAVENCIO's market uptake has been driven by its in the urothelial carcinoma maintenance setting, where it demonstrated a significant survival benefit. The drug has gained traction in major markets like the U.S., Europe , and Japan , benefiting from . However, its adoption has been tempered by and around cost-effectiveness, especially in competitive oncology segments.
One of BAVENCIO's primary challenges is its limited label expansion compared to blockbuster PD-1 inhibitors like (nivolumab) and . While its urothelial carcinoma approval has a strong foothold, its like NSCLC constrains its market potential. Nonetheless, exploring novel combination strategies with other immunotherapies and targeted agents could enhance its market positioning. Additionally, offer opportunities for future growth.
The future of BAVENCIO will largely depend on its and differentiate itself in the crowded IO space. With on the horizon, strategic partnerships, real-world evidence generation, and market access strategies will be crucial in sustaining its commercial success.
Dive deeper to get more insight into BAVENCIO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key urothelial carcinoma companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key urothelial carcinoma companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key merkel cell carcinoma companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key renal cell carcinoma companies including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bavencio-continues-to-strengthen-its-position-in-the-immuno-oncology-landscape--delveinsight-302396598.html